Wellington Partners
Rigontec today announced the dosing of the first patient in a phase I/II study with intratumoral/intralesional administration of its lead compound RGT100 in solid tumors and lymphoma. In addition, Rigontec appoints industry veteran Prof. Eugen Leo as Chief Medical Officer.
Austrian biotech company Themis Bioscience said it had started a clinical trial of an experimental Zika vaccine in healthy volunteers.
Symetis has announced that it has agreed to be acquired by Boston Scientific in an all cash, up-front payment.
Page 7 of 15
